To deliver treatments for rare diseases more quickly, companies share how they are adapting their launch strategies and ...

A study led by Queen Mary University of London has found 69 previously unidentified genetic determinants of rare diseases.

Eli Lilly has unveiled plans to invest at least $27bn in building four new pharmaceutical manufacturing sites in the US.

Around the world, events are being held to mark Rare Disease Day (28 February 2025), with the aim of bringing attention to rare diseases and improving access to diagnosis and therapies for patients.

Avtozma, which is Celltrion’s twelfth biosimilar to be approved by the EC, is a recombinant humanised monoclonal antibody ...

Just in time for Women’s History Month and International Women’s Day on March 8th, Medscape is proud to showcase its ...

The phase 3 SERENA-6 study randomised patients with HR-positive, HER2-negative advanced breast cancer whose tumours had an ...

Johnson & Johnson (J&J) has shared positive results from a late-stage study evaluating a subcutaneous (SC) version of Tremfya ...

NHS England has announced that it has appointed Sir James Mackey as its new chief executive officer (CEO), following Amanda ...

Amgen’s Blincyto (blinatumomab) has been recommended by the National Institute for Health and Care Excellence (NICE) to treat ...

Coming in first on the list of Top 25 Pharma Companies US Rx is AbbVie, reaching $41,857m in US Rx revenue in 2023 and ...

Gilead Sciences’ seladelpar has been granted conditional marketing authorisation by the European Commission (EC) to treat ...